BioWorld data methodology

Clinical data

Phase 1 - 2026	Phase II - 2026	Phase III - 2026	Regulatory - 2026
Phase 1 - 2025	Phase II - 2025	Phase III - 2025	Regulatory - 2025
Phase 1 - 2024	Phase II - 2024	Phase III - 2024	Regulatory - 2024
Phase 1 - 2023	Phase II - 2023	Phase III - 2023	Regulatory - 2023
Phase 1 - 2022	Phase II - 2022	Phase III - 2022	Regulatory - 2022
Phase I - 2021	Phase II - 2021	Phase III - 2021	Regulatory - 2021
Phase I - 2020	Phase II - 2020	Phase III - 2020	Regulatory - 2020

Products approved by U.S. FDA

2026	2025	2024	2023	2022
2021	2020	2019	2018	2017
2016	1982-2015

Global products approved

2026

Drugs on deck

2026

IPOs

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000	1999

Follow-on offerings

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000

Public/other financings

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000	1999

Venture capital financings

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000	1999

Biopharma company deals

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000	1999

Mergers and acquisitions

2026	2025	2024	2023	2022	2021
2020	2019	2018	2017	2016	2015
2014	2013	2012	2011	2010	2009
2008	2007	2006	2005	2004	2003
2002	2001	2000	1999